Welcome to our dedicated page for BIOLASE news (Ticker: BIOL), a resource for investors and traders seeking the latest updates and insights on BIOLASE stock.
Biolase, Inc. (NASDAQ: BIOL) is a leading medical device company specializing in the development, manufacturing, marketing, and sales of advanced laser systems used in dentistry and medicine. Based in the United States, the company is recognized globally for its innovative dental laser technologies that enhance dental care by enabling clinicians to perform a wide range of minimally invasive procedures, reducing patient pain, fear, and anxiety typically associated with dental treatments.
Biolase’s flagship products are categorized into two primary groups: Waterlase (all-tissue) systems and Diode (soft-tissue) systems. These products cater to various dental professionals, including general dentists, periodontists, endodontists, and oral surgeons, allowing them to execute procedures ranging from simple restorations to complex surgical interventions. The company’s revenue is predominantly derived from the U.S. market, but its impact is felt worldwide, having sold over 47,700 laser systems across more than 80 countries.
In recent developments, Biolase has expanded its educational initiatives, recognizing the growing demand for knowledge in dental laser technologies. The company launched new courses through its Education.Biolase.com portal, offering both in-person and virtual training through the Waterlase Academy and Epic Diode Academy. This educational expansion includes specialized courses in endodontics, periodontics, pediatric dentistry, and facial esthetics. Notably, Biolase unveiled the Waterlase iPlus Premier Edition at the Chicago Midwinter Meeting 2024, which represents a significant innovation in all-tissue laser systems.
Financially, Biolase has shown resilience amidst challenging market conditions. For the year ending December 31, 2023, the company reported net revenues of $49.2 million, a slight increase compared to the previous year. Despite a decrease in U.S. laser sales, the company saw a 31% increase in U.S. consumables and other revenue. The company is actively optimizing its operations and has undertaken cost-reduction measures, including a workforce reduction projected to save approximately $2.5 million annually.
Looking ahead, Biolase continues to focus on driving the adoption of its dental laser systems and expanding its educational offerings. The company aims to achieve long-term growth and profitability through strategic initiatives and product innovations. For further updates and information, visit www.biolase.com or follow Biolase on various social media platforms.
BIOLASE, Inc. (NASDAQ: BIOL) has launched a new e-commerce website aimed at improving the purchasing experience for U.S. dental practitioners. The site, store.biolase.com, features a user-friendly design and allows users to link their bank accounts for streamlined ordering. It offers product suggestions based on browsing history and will spotlight different BIOLASE dentists quarterly, providing tips for laser procedures. Executives believe this initiative will increase laser adoption and enhance patient care efficiency.
BIOLASE has launched the Waterlase Fractional Handpiece in the U.S., enhancing skin resurfacing treatments with faster healing and recovery times. The handpiece is FDA 510(k) cleared and operates on the Waterlase iPlus platform, delivering both ablative and non-ablative treatments. Its proprietary water spray allows for procedures without anesthetics, improving patient comfort. BIOLASE targets the $215 million skin resurfacing market, aiming to increase the adoption of its technology in the dental industry. The handpiece has also shown success in international markets, providing effective solutions in cosmetic procedures.
BIOLASE, Inc. (NASDAQ: BIOL) has launched a new education web portal, Education.Biolase.com, enhancing its educational initiatives for dental professionals. The portal includes the Waterlase Academy and Epic Diode Academy, which provide tailored pathways for laser education. Offerings feature live seminars, classroom training, on-demand webinars, and extensive resources such as clinical video and animation libraries. BIOLASE aims to elevate dental care standards through this initiative, tapping into its 302 patented technologies designed to improve patient outcomes.
BIOLASE, a leader in dental lasers, will present at the Third Annual Winter Wonderland Best Ideas Virtual Investor Conference from February 21-24, 2023. The presentation is scheduled for February 21 at 2:00 p.m. PT (5:00 p.m. ET), with management hosting one-on-one meetings on February 23-24. This event is an opportunity for investors to learn more about BIOLASE's innovations in dental technology, comprising over 301 patents and 28 patent-pending technologies. For more information or to request an invitation, email angie.wright@issuerdirect.com. The presentation will be accessible via ir.biolase.com.
Strateos, a leader in lab automation and remote access labs, announced key management appointments aimed at enhancing growth and technology innovation. Alexander K. Arrow, MD, CFA, has been appointed Chief Financial Officer, while Juliet M. Moritz, MPH, will serve as Vice President of the Project Management Office. Arrow's extensive experience in finance and medical technology will guide the company's financial strategy, while Moritz will oversee the deployment of the Lodestar Software, crucial for drug discovery processes. These appointments come in response to increasing demand from pharmaceutical firms for Strateos' innovative services.
On January 25, 2023, BIOLASE, Inc. (NASDAQ: BIOL) publicly responded to Sonendo, Inc.'s patent litigation, deeming the claims 'meritless' and an attempt to undermine BIOLASE's market position. BIOLASE, known for its dental laser innovations, asserts that Sonendo's claims overlap with conventional technologies and lack true innovation. The company's CEO, John Beaver, criticized Sonendo's product quality and referred to an FDA Class 2 device recall concerning Sonendo's GentleWave system. BIOLASE plans to vigorously defend against the claims and emphasizes its position in the market, aiming to expand its share with superior products and robust intellectual property.
On January 25, 2023, BIOLASE (NASDAQ: BIOL) responded to Sonendo's legal claims regarding patent infringement. BIOLASE regards these claims as meritless and intends to challenge them vigorously, asserting that they overlap with existing technologies. John Beaver, CEO of BIOLASE, criticized Sonendo's products as inferior and costly, referencing a recent FDA recall on its GentleWave system. BIOLASE emphasizes its commitment to maintaining market leadership through innovative laser technology and a robust intellectual property portfolio, with over 302 patents and extensive global sales.
BIOLASE, Inc., a leader in dental lasers, announced that preliminary revenue for Q4 2022 is expected between $14.0 million and $14.4 million, representing a 13% to 16% increase from Q4 2021. Full-year 2022 revenue is anticipated to reach $48.4 million to $48.8 million, a growth of 24% to 25% compared to the previous year. The company highlights strong adoption of its Waterlase products, with 84% of sales coming from new customers. Looking ahead, BIOLASE aims for at least 25% revenue growth in 2023, positive adjusted EBITDA, and further market penetration through various initiatives.
FAQ
What is the current stock price of BIOLASE (BIOL)?
What is the market cap of BIOLASE (BIOL)?
What are the main products offered by Biolase, Inc.?
Where can I find educational resources on Biolase's dental lasers?
How has Biolase performed financially in recent years?
What recent innovations has Biolase introduced?
What is Biolase's strategy for long-term growth?
What markets does Biolase primarily serve?
What is the significance of Biolase's educational initiatives?
How can investors stay informed about Biolase's financial performance?
What are the advantages of using Biolase's laser systems in dentistry?
Where can I find more information about Biolase's products and updates?
